EXINI Diagnostics AB
EXINI: Bone Scan Index (BSI) as therapy-monitoring imaging biomarker, to be presented at the 2014 German Congress for Urology, DGU, in Düsseldorf
DGAP-News: EXINI Diagnostics AB / 24.06.2014 / 08:55 --------------------------------------------------------------------- Lund, Sweden, 2014-06-24 08:55 CEST (GLOBE NEWSWIRE) -- The Martini Clinic, renowned German Prostate Cancer Centre at the University of Hamburg, UKE, will present a study based on PCa-patients undergoing advanced treatment with the drug substance Abiraterone, at this year's annual German Congress for Urology (DGU) in Düsseldorf. The study was performed by the Martini clinic, Autumn 2013 through spring 2014, on patients treated for metastasized prostate cancer. The patients were monitored using the software EXINI boneBSI, which automatically calculate and provide BSI-value to attending physicians and staff. Results from the study will be orally presented at the DGU-congress, demonstrating BSI as a reliable biomarker in monitoring disease progress and treatment response. The DGU-presentation title: Automated quantification of the metastatic burden of castration resistant prostate cancer patients: Observer independent monitoring of disease progression. (Automatisierte Quantifizierung der Metastasenlast bei kastrations-resistenten Prostatakarzinompatienten: Untersucher-unabhängiges Monitoring des Krankheitsverlaufes) 'An oral presentation at the prestigious DGU-congress is a success and an acknowledgment to our work on the German market', remarks Fredrik Luttropp, Sales Manager Germany, EXINI Diagnostics AB. For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 600 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser. ________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 24.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: EXINI Diagnostics AB Sweden ISIN: SE0001810284 End of News DGAP News-Service --------------------------------------------------------------------- 274810 24.06.2014
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden